Long-acting G-CSF for Febrile Neutropenia

• Status: Recruiting
• Trial end date: 2023-11-10
• Target enrollment: 0
• Participant gender: Female

Summary

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lei Li
• Treatments: Lenograstim; Sargramostim

Criteria

Inclusion Criteria:

• Willing to accepted debulking surgeries and adjuvant chemotherapy

• Good performance status

• Aged 18 years or older

• Signed an approved informed consents

• No immunosuppressive disease

Exclusion Criteria:

• Not meeting all of the inclusion criteria